The Impact of ICH E6 (R3) on Protocol Development – Practical Implications for Protocol Writers

also published on LinkedIn March 16, 2025

The recently published ICH E6 (R3) Good Clinical Practice guidance is set to bring significant changes to the development of clinical trial protocols. The European Medicines Agency (EMA) has adopted E6(R3) Principles and Annex 1 to take effect on July 23, 2025. Other ICH member nations and regions are still in the process of considering E6(R3) implementation. Additionally, Annex 2, which provides guidance on pragmatic and decentralized clinical trials as well as trials incorporating real-world data, is expected to be finalized by ICH later this year.

As the biopharmaceutical industry continues to evolve toward more complex and adaptive study designs, clinical development teams and protocol writers must align expectations and approaches with these new regulatory expectations. Understanding the key updates in ICH E6 (R3) and their practical implications in enhancing protocol clarity, compliance, and efficiency is essential for those involved in protocol development.

Key Changes in ICH E6 (R3)
The primary goal of ICH E6 (R3) is to modernize GCP guidance by emphasizing quality by design, risk-based approaches, and data integrity. The guidance states the following:

• The scientific objectives of any trial should be clear and explicitly stated in the protocol.
• The clinical trial protocol as well as the plans or documents for the protocol execution (that is, statistical analysis plan, and monitoring plan, should be clear, concise, and operationally feasible.

Some of the major (R3) updates that impact protocol development include:

1. Quality by Design (QbD) Principles – Protocols must integrate risk-based thinking from the outset. This means sponsors will have to proactively identify and mitigate risks throughout the trial lifecycle—from design to conduct and to reporting.
2. Greater Emphasis on Risk-Based Monitoring – ICH E6 (R3) stipulates protocols should clearly define critical-to-quality factors that influence study reliability and patient safety. Regulatory experts stress that ICH E6 (R3) reinforces risk-based quality management as a core requirement, urging sponsors and CROs to adopt proactive risk identification in study design and monitoring.
3. Clarification of Roles and Responsibilities – This section was added to provide clearer expectations for all clinical stakeholders involved in a clinical research project.
4. Increased Focus on Data Integrity and Transparency – Protocols must outline data collection, handling, transfer, analysis, and security measures in a way that ensures reliability and reproducibility. The guidance also mentions that the information collected on each study participant is scaled to address the trial objectives.
5. Flexibility in Study Design – The revision recognizes the growing use of decentralized clinical trials (DCTs), adaptive trial designs, tele-health, remote data collection, and real-world evidence approaches.
6. Patient-Centric Considerations – There is an increased focus on patient involvement in study design to enhance protocol feasibility and recruitment, and reduce participant burden.

To align with these changes, protocol writers must consider the following concepts:
Structuring Protocols with a Risk-Based Mindset

1. Clearly define how study objectives link to study purpose and prioritize critical-to-quality factors. This concept is all about rationale. In essence, put into writing that is clear and concise how the study will answer the research question.
2. Minimize unnecessary complexity by focusing on essential study parameters.
3. Integrate risk mitigation strategies directly into protocol sections. This concept will require concise and precise language.

Enhancing Clarity in Monitoring and Data Collection Plans

1. Define data collection processes in the protocol with an emphasis on data quality and integrity. This principle now requires more than just saying what we are doing. There is a need to offer rationale of why this plan.
2. Specify risk-based monitoring approaches tailored to the study design.
3. Ensure consistency between protocol procedures and study oversight plans.

Addressing Decentralized and Adaptive Study Considerations

1. Incorporate clear guidelines for remote data collection and telemedicine visits. Hereto, we are talking about ensuring the representation of concepts are clear and written with precise language.
2. Ensure flexibility in study designs is clearly documented and will maintain regulatory compliance.
3. Detail the conditions under which protocol modifications may be implemented without compromising scientific rigor.

Strengthening Patient-Centered Language and Accessibility

1. Use plain language principles where possible to enhance protocol readability for all stakeholders. This concept is grounded in all the principles of lean writing.
2. Clearly describe participant responsibilities, visit schedules, and expected study burdens.
3. Incorporate input from patient advocacy groups where it is feasible to improve study design.

Conclusion
ICH E6(R3) ultimately aims to improve trial efficiency, participant experience, and data reliability. Protocol writers will play a critical role by translating these updated regulatory expectations into clear, actionable, and compliant documents.